Relapse patterns and outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study
Authors:
- On behalf of the SIOP-E Brain Tumour GroupOGOn behalf of the SIOP-E Brain Tumour Group
- Magnus SabelMSMagnus Sabel
- François DozFDFrançois Doz
- Maura MassiminoMaura Massimino
Open Access
- 16 July 2016
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 129 (3) , 515-524
Abstract
The HIT-SIOP-PNET4 randomised trial for standard risk medulloblastoma (MB) (2001–2006) included 338 patients and compared hyperfractionated and conventional radiotherapy. We here report the long-term outcome after a median follow up of 7.8 years, including detailed information on relapse and the treatment of relapse. Data were extracted from the HIT Group Relapsed MB database and by way of a specific case report form. The event-free and overall (OS) survival at 10 years were 76 ± 2 % and 78 ± 2 % respectively with no significant difference between the treatment arms. Seventy-two relapses and three second malignant neoplasms were reported. Thirteen relapses (18 %) were isolated local relapses in the posterior fossa (PF) and 59 (82 %) were craniospinal, metastatic relapses (isolated or multiple) with or without concurrent PF disease. Isolated PF relapse vs all other relapses occurred at mean/median of 38/35 and 28/26 months respectively (p = 0.24). Late relapse, i.e. >5 years from diagnosis, occurred in six patients (8 %). Relapse treatment consisted of combinations of surgery (25 %), focal radiotherapy (RT 22 %), high dose chemotherapy with stem cell rescue (HDSCR 21 %) and conventional chemotherapy (90 %). OS at 5 years after relapse was 6.0 ± 4 %. In multivariate analysis; isolated relapse in PF, and surgery were significantly associated with prolonged survival whereas RT and HDSCR were not. Survival after relapse was not related to biological factors and was very poor despite several patients receiving intensive treatments. Exploration of new drugs is warranted, preferably based on tumour biology from biopsy of the relapsed tumour.Keywords
Funding Information
- Barncancerfonden
- Deutsche Kinderkrebsstiftung
- Cancer Research UK
- the French Ministry of Health
- Institut National Du Cancer
- Associazione Bianca Garavaglia Onlus
This publication has 23 references indexed in Scilit:
- Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trialOncotarget, 2015
- Combined MYC and P53 Defects Emerge at Medulloblastoma Relapse and Define Rapidly Progressive, Therapeutically Targetable DiseaseCancer Cell, 2015
- Treatment of recurrent primitive neuroectodermal tumors (PNET) in children and adolescents with high-dose chemotherapy (HDC) and stem cell support: results of the HITREZ 97 multicentre trialJournal of Neuro-Oncology, 2014
- Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysisThe Lancet Oncology, 2013
- Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961Neuro-Oncology, 2012
- Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 TrialJournal of Clinical Oncology, 2012
- MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastomaActa Neuropathologica, 2011
- Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk MedulloblastomaJournal of Clinical Oncology, 2006
- β-Catenin Status Predicts a Favorable Outcome in Childhood Medulloblastoma: The United Kingdom Children's Cancer Study Group Brain Tumour CommitteeJournal of Clinical Oncology, 2005
- Improving survival in recurrent medulloblastoma: earlier detection, better treatment or still an impasse?British Journal of Cancer, 1998